4.7 Article

Gender differences in dopaminergic system dysfunction in de novo Parkinson's disease clinical subtypes

期刊

NEUROBIOLOGY OF DISEASE
卷 167, 期 -, 页码 -

出版社

ACADEMIC PRESS INC ELSEVIER SCIENCE
DOI: 10.1016/j.nbd.2022.105668

关键词

Gender; Idiopathic Parkinson's disease subtypes; Dopaminergic pathways; [123I]FP-CIT SPECT; Molecular connectivity

资金

  1. Michael J. Fox Foundation for Parkinson's Research
  2. 4D Pharma
  3. Abbvie
  4. Acurex Therapeutics
  5. Allergan
  6. Amathus Therapeutics
  7. ASAP
  8. Avid Radiopharmaceuticals
  9. Bial Biotech
  10. Biogen
  11. BioLegend
  12. Bristol-Myers Squibb
  13. Calico
  14. Celgene
  15. Dacapo Brain Science
  16. Denali
  17. Edmond J. Safra Foundaiton
  18. GE Healthcare
  19. Genentech
  20. GlaxoSmithKline
  21. Golub Capital
  22. Handl Therapeutics
  23. Insitro
  24. Janssen Neuroscience
  25. Lilly
  26. Lundbeck
  27. Merck
  28. Meso Scale Discovery
  29. Neurocrine Biosciences
  30. Pfizer
  31. Piramal
  32. Prevail
  33. Roche
  34. Sanofi Genzyme
  35. Servier
  36. Takeda
  37. Teva
  38. UCB
  39. Verily
  40. Voyager Therapeutics

向作者/读者索取更多资源

This study investigated the impact of gender differences on clinical features, dopaminergic dysfunction, and connectivity in patients with Parkinson's disease across different clinical subtypes. Results showed that males and females with idiopathic PD exhibit distinct vulnerabilities and disease expressions, particularly in cognitive function, anxiety symptoms, and dopaminergic binding patterns in different brain regions.
Parkinson's disease (PD) is characterized by heterogeneity in clinical syndromes, prognosis, and pathophysiology mechanisms. Gender differences in neural anatomy and function are emerging as fundamental determinants of phenotypic variability. Different clinical subtypes, defined as mild motor predominant, intermediate, and diffuse-malignant, have been recently proposed in PD. This study investigated gender influence on clinical features, dopaminergic dysfunction, and connectivity in patients with de novo idiopathic PD stratified according to the clinical criteria for subtypes (i.e., mild motor, intermediate, and diffuse-malignant). We included 286 drug-naive patients (Males/Females: 189/97, age [mean +/- standard deviation]: 61.99 +/- 9.67; disease duration: 2.08 +/- 2.21) with available [123I]FP-CIT-SPECT and high-resolution T1-weighted MRI from the Parkinson's Progression Markers Initiative. We assessed gender differences for clinical and cognitive features, and dopaminergic presynaptic dysfunction in striatal or extra-striatal regions using molecular analysis of [123I]FP-CIT-bindings. We applied an advanced multivariate analytical approach - partial correlations molecular connectivity analyses - to assess potential gender differences in the vulnerability of the nigrostriatal and mesolimbic dopaminergic pathways. In the mild motor and intermediate subtypes, male patients with idiopathic PD showed poorer cognitive performances than females, who - in contrast - presented more severe anxiety symptoms. The male vulnerability emerged also in the motor system in the same subtypes with motor impairment associated with a lower dopamine binding in the putamen and more severe widespread connectivity alterations in the nigrostriatal dopaminergic pathway in males than in females. In the diffuse-malignant subtype, males showed more severe motor impairments, consistent with a lower dopamine uptake in the putamen than females. On the other hand, a severe dopaminergic depletion in several dopaminergic targets of the mesolimbic pathway, together with extensive altered connectivity in the same system, characterized females with idiopathic PD in all the subtypes. The anxiety level was associated with a lower dopaminergic binding in the amygdala only in females. This study provides evidence on gender differences in idiopathic PD across clinical subtypes, and, remarkably, since the early phase. The clinical correlations with the nigrostriatal or mesolimbic systems in males and females support different vulnerabilities and related disease expressions. Gender differences must be considered in a precision medicine approach to preventing, diagnosing, and treating idiopathic PD.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据